AASLD 2014: DAAs Show Good Cure Rates and Liver Function Improvement for Transplant Recipients with Recurrent HCV
- Category: Approved HCV Drugs
- Published on Tuesday, 25 November 2014 00:00
- Written by Liz Highleyman
A variety of interferon-free regimens containing the direct-acting antivirals sofosbuvir (Sovaldi), simeprevir (Olysio), and daclatasvir (Daklinza) led to high sustained virological response rates, often improved liver function, and were generally safe and reasonably well-tolerated by liver transplant recipients with hepatitis C recurrence, one of the most difficult populations to treat, according to several presentations at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting this month in Boston.